dr tarhini on the utility of a prognostic model in advanced melanoma following ici treatment
Published 2 months ago • 17 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
2:06
dr tarhini on hogh-dose bolus il-2 with ipilimumab followed by nivolumab in melanoma
-
2:06
dr. tarhini discusses adjuvant therapy for melanoma
-
2:04
dr. tarhini on recent practice-changing clinical trials in melanoma
-
4:25
the phenomenon of immunotherapy in melanoma
-
7:00
metastatic melanoma: the immunotherapy approach
-
0:58
dr. tawbi on checkpoint inhibition in melanoma
-
30:40
systemic therapy for advanced melanoma
-
8:04
choosing the right therapy for melanoma
-
2:01
dr. tawbi on evolving treatment for melanoma
-
10:54
immunotherapy in melanoma
-
7:24
immunotherapy in melanoma: recognizing an endocrinopathy
-
10:42
what is new in melanoma?
-
4:22
recurrent melanoma: prognostical factors to consider
-
1:42
dr. triebel on the rationale for a novel immunotherapy combination in melanoma
-
4:32
overall toxicities with immunotherapy in melanoma
-
1:18
dr. shoushtari on the data from the first-in-human trial for tebentafusp in advanced melanoma
-
10:35
measuring response to immunotherapy in melanoma
-
11:16
immunotherapy for melanoma, pt. 2: immune checkpoints & the drugs that block them
-
7:11
checkpoint inhibitors in metastatic melanoma